In the present study, we assessed the relation between diastolic dysfunction (measured by technetium-99m radionuclide ventriculography) and serum levels of myocardial fibrosis markers (aminoterminal propeptides of type I and III procollagen; PINP and PIIINP) in hypertensive patients without diabetes mellitus. Patients with abnormal PINP level (453 lg/l) had significantly lower left ventricular peak filling rate (PFR) and shorter time to PFR than patients with normal PINP level (p53 lg/l). Elevated serum PINP level reflected diastolic dysfunction in hypertensive patients without diabetes.
Arterial hypertension stimulates both myocardial procollagen gene expression and collagen synthesis. The excess deposit of myocardial collagen content results in myocardial stiffness and diastolic dysfunction. 1, 2 The conventional methods to evaluate diastolic function are Doppler echocardiography and radionuclide ventriculography. However, their uses are limited by cost considering the large number of hypertensive patients. Therefore, biochemical methods for detecting diastolic dysfunction are required. Recently, non-invasive evaluation of myocardial fibrosis by using serological markers of collagen I and III turnover has been reported. These markers provide valuable diagnostic information on the extent of myocardial fibrosis. [2] [3] [4] We hypothesized that serological markers of collagen turnover can offer additional values for evaluating diastolic dysfunction in hypertensive patients. Therefore, we conducted this prospective study to evaluate the relation between serum markers of myocardial fibrosis and diastolic dysfunction.
We enroled 20 medically treated ambulatory, non-diabetic, hypertensive patients in this study. Patients with abnormal liver functions, leucocytosis, elevated serum levels of C-reactive protein, systolic dysfunction (left ventricular (LV) ejection fraction o50%) and LV hypertrophy due to etiologies other than hypertension were excluded. All patients underwent blood sampling for evaluation of serum concentrations of PINP and PIIINP and examinations of diastolic dysfunction by echocardiography and technetium-99m ( 99m Tc) radionuclide ventriculography. According to the range of serum PINP concentration in hypertensive patients without LV diastolic dysfunction. (7.6-53.1 mg/l), 5 patients were divided in two groups: group 1 patients with PINP p53 mg/l, and group2 patients with PINP453 mg/l. The study was approved by the ethical committee of the National Taiwan University Hospital and all subjects gave informed consent including blood sampling, echocardiography, and 99m Tc radionuclide ventriculography before enroled.
Serum PINP and PIIINP were determined by a rapid equilibrium radioimmunoassay using commercial antisera specifically directed against the amino-terminal propeptide (Orion Diagnostica, Espoo, Finland). 3, 4 Echocardiographic studies including two-dimensional, M-mode and Doppler ultrasound recordings were performed. LV dimension, septum and posterior wall thickness, LV mass index (LVMI), E/A ratio of mitral flow, deceleration time of E flow, velocities of pulmonary venous flow, isovolumetric relaxation time and Tei index were measured according to routine methodology (Table 1) .
In 99m Tc radionuclide ventriculography, a total of 20 mCi 99m Tc-labelled RBCs were injected intravenously. The global LV/right ventricular (RV) ejection fraction were calculated by using the semiautomatic edge detection and count technique. The LV and RV filling/emptying rates were determined from the derivatives of the time-activity curve. PFR (end-diastolic volume/second; EDV/s) and time to PFR (ms) were obtained.
All A total of 20 patients were enroled into this study (five men and 15 women; mean age was 64 years). There were eight patients with PINP p53 mg/l (group 1), and 12 patients with PINP453 mg/l (group 2). No statistical differences of age, incidence of hyperlipidaemia, or pharmacological treatment of antihypertensive agents were measured between two groups. Patients in group 2 had significant higher serum PINP level (Po0.001) and comparable serum PIIINP level. There was no correlation between serum PINP and PIIINP level.
No statistical differences of echocardiographic parameters for LV diastolic dysfunction (E/A ratio of mitral flow, deceleration time of E flow, velocities of pulmonary venous flow (retrograde A wave, systolic/diastolic velocity ratio), isovolumetric relaxation time, Tei index) were found between two groups. In 99m Tc radionuclide ventriculography, the ejection fractions of both ventricles were comparable between two groups. In LV diastolic function assessment, patients in group 2 had significantly lower PFR (Po0.05) and shorter time to PFR (Po0.05). Besides, the group 2 patients also had borderline lower right ventricle PFR (P ¼ 0.082) and shorter time to PFR (P ¼ 0.098). In multiple regression analysis, LV time to PFR was the only parameter that independently predicted serum PINP level (Po0.05).
The present study demonstrated that hypertensive patients with increased serum PINP level had abnormal diastolic filling pattern in both ventricles. The PINP is an extension peptide of procollagen type I, which is cleaved off during conversion from type I procollagen to type I collagen. Increased serum PINP level reflects increased type I collagen formation, which makes myocardial wall stiffer and diastolic dysfunction. The close relationship of myocardial fibrosis and diastolic dysfunction has also been reported. 6 Compared to normotensive control, hypertensive patients tend to have lower PFR in radionuclide ventriculography. [7] [8] [9] This change is considered as diastolic abnormalities related to impaired relaxation. Despite the uniform decrease of PFR in hypertensive patients, the time to PFR varies among studies. 7, 10 The increase of time to PFR is positively correlated with the LVMI in echocardiography and the presence of LVH in electrocardiogram. 8, 9 In the present study, patients in group 2 with higher serum PINP level had lower PFR and shorter time to PFR in both ventricles. Patients in both group had similar LVMI, but patients with more cardiac fibrosis had shorter time to PFR. The stiffer myocardium related to cardiac fibrosis might explain this restrictive physiology of LV filling in group 2 patients. Our data was compatible with the previous report. 11 In the present study, there are no statistical differences of echocardiographic parameters for LV diastolic dysfunction between two groups. The discrepancy between serum markers for cardiac fibrosis and echocardiographic parameters for diastolic dysfunction have been also described previously. 5 The present study had limitations. First, there was lack of tissue samples to assess the extent of myocardial fibrosis. However, obtaining ventricular muscle biopsies in asymptomatic patients with hypertension is unethical in this hospital. Second, we do not use tissue Doppler in this study, which is recently proven as a sensitive tool to detect diastolic dysfunction. 12 This may decrease the sensitivity to detect diastolic dysfunction in echocardiography. Third, the patient number was small. This may yield to alpha or beta type errors in statistical analysis. Further large-scale studies are needed.
